Although sorafenib, a tyrosine kinase inhibitor with VEGF inhibitory activity, has a relatively mild inhibition compared with other tyrosine kinase inhibitors approved for HCC [21–23], such as lenvatinib, our patient cohort had previously received bevacizumab, an anti-VEGF antibody, and lenvatinib as first- and second-line therapy. This evidence concerns the gene VEGFA and hepatocellular carcinoma.